Search

Displaying results 3471 - 3480 of 10000 in total
  1. Drug

    Recombinant Cholera Toxin B Subunit

    go.drugbank.com/drugs/DB11643
    ApprovedInvestigational

    Recombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Pyruvic acid

    go.drugbank.com/drugs/DB00119
    ApprovedInvestigationalNutraceutical

    (From Stedman, 26th ed) … An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures.

  3. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition

  4. Drug

    Edetic acid

    go.drugbank.com/drugs/DB00974
    ApprovedInvestigationalVet approved

    It is used in pharmaceutical manufacturing and as a food additive.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)
  5. Drug

    Propylparaben

    go.drugbank.com/drugs/DB14177
    Approved

    Propylparaben is used in allergenic testing.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: n-propyl paraben, n-Propyl 4-hydroxybenzoate
  6. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    [A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130] … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.

  7. Drug

    Profenamine

    go.drugbank.com/drugs/DB00392
    Approved

    It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]

    Synonyms: N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine, N,N-diethyl-α-methyl-10H-phenothiazine-10-ethanamineProducts: Parsitan 50
  8. Target

    Dihydrolipoyl dehydrogenase

    go.drugbank.com/bio_entities/BE0002965
    TargetAzotobacter vinelandii

    The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2).

    Synonyms: E3 component of pyruvate complex
  9. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.

  10. Drug

    Antazoline

    go.drugbank.com/drugs/DB08799
    Approved

    Antazoline is a 1st generation antihistamine with anticholinergic activity. It is used to relieve nasal congestion. It is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis.

    Synonyms: 2-(N-Phenyl-N-benzylaminomethyl)imidazoline, 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamineMixtures: SULFARHIN BURUN MERHEMI, 20 G, SULFARHIN BURUN MERHEMI, 12 G